RECOVERED HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT (VERSIONS), METHOD OF TREATING hTNFα-MEDIATED DISEASES WITH MEDIATION THEREOF (VERSIONS), PHARMACEUTICAL COMPOSITION, RECOMBINANT HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT, RECOVERED NUCLEIC ACID (VERSIONS) Russian patent published in 2012 - IPC A61K39/00 

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to human antibodies, preferentially recombinant human antibodies which are characterized by specific binding with tumour necrosis factor a (hTNFα). The antibodies show high affinity to hTNFα (K_d=10^-8 M or less), low dissociation rate (K_off=10^-3 s^-1 or less) and neutralise hTNFα activity in vitro and in vivo. The antibodies under the invention can be a full-length antibody or its antigen-binding fragment. The antibodies or antibody fragments under the invention are effective in hTNFα detection and in hTNFα activity inhibition in pathologies and/or diseases, e.g. human hTNFα-mediated diseases.

EFFECT: inventions also cover nucleic acids, expression vectors of recombinant human antibodies and pharmaceutical compositions on the basis of human antibodies.

52 cl, 11 dwg, 17 tbl, 4 ex